leuprorelin sandoz implant in syringe 5 mg
sandoz singapore pte. ltd. - leuprorelin acetate eqv. leuprorelin - implant - leuprorelin acetate eqv. leuprorelin 5.0 mg
eligard leuprorelin acetate 30mg modified release injection syringe
mundipharma pty ltd - leuprorelin acetate, quantity: 30 mg - injection, modified release - excipient ingredients: n-methyl-2-pyrrolidone; polyglactin - prostate cancer,eligard 7.5mg 1 month, eligard 22.5mg 3 month, eligard 30mg 4 month and eligard 45mg 6 month are indicated for the:,? palliative treatment of advanced prostate cancer.,? treatment of high-risk localised and locally advanced hormone-dependent prostate cancer in combination with radiotherapy.
eligard leuprorelin acetate 22.5mg modified release injection syringe
mundipharma pty ltd - leuprorelin acetate, quantity: 22.5 mg - injection, modified release - excipient ingredients: n-methyl-2-pyrrolidone; polyglactin - prostate cancer,eligard 7.5mg 1 month, eligard 22.5mg 3 month, eligard 30mg 4 month and eligard 45mg 6 month are indicated for the:,? palliative treatment of advanced prostate cancer.,? treatment of high-risk localised and locally advanced hormone-dependent prostate cancer in combination with radiotherapy.
eligard leuprorelin acetate 7.5mg modified release injection syringe
mundipharma pty ltd - leuprorelin acetate, quantity: 7.5 mg - injection, modified release - excipient ingredients: n-methyl-2-pyrrolidone; polyglactin - eligard 7.5mg 1 month, eligard 22.5mg 3 month, eligard 30mg 4 month and eligard 45mg 6 month are indicated for the:,? palliative treatment of advanced prostate cancer.,? treatment of high-risk localised and locally advanced hormone-dependent prostate cancer in combination with radiotherapy.1
lucrin depot 1-month
abbvie limited - leuprorelin acetate 3.75mg (powder for injection compartment) - injection (depot) - 3.75 mg - active: leuprorelin acetate 3.75mg (powder for injection compartment) excipient: acetic acid carmellose sodium gelatin plga (copoly (dl-lactic acid/glycolic acid) 75:25mol%) powder for injection compartment mannitol polysorbate 80 water for injection - lucrin (leuprorelin acetate) is indicated · in metastatic prostate cancer · in locally advanced prostate cancer, as an alternative to surgical castration · as an adjuvant treatment to radiotherapy in patients with high-risk localized or locally advanced prostate cancer · as an adjuvant treatment to radical prostatectomy in patients with locally advanced prostate cancer at high risk of disease progression
lucrin depot 3-month
abbvie limited - leuprorelin acetate 11.25mg (powder for injection compartment) - injection (depot) - 11.25 mg - active: leuprorelin acetate 11.25mg (powder for injection compartment) excipient: carmellose sodium glacial acetic acid polylactic acid (pla) powder for injection compartment mannitol polysorbate 80 water for injection - lucrin (leuprorelin acetate) is indicated · in metastatic prostate cancer · in locally advanced prostate cancer, as an alternative to surgical castration · as an adjuvant treatment to radiotherapy in patients with high-risk localized or locally advanced prostate cancer · as an adjuvant treatment to radical prostatectomy in patients with locally advanced prostate cancer at high risk of disease progression
lucrin depot 6-month
abbvie limited - leuprorelin acetate 30mg (powder for injection compartment) - injection (depot) - 30 mg - active: leuprorelin acetate 30mg (powder for injection compartment) excipient: carmellose sodium glacial acetic acid lactic acid mannitol polysorbate 80 water for injection - lucrin (leuprorelin acetate) is indicated · in metastatic prostate cancer · in locally advanced prostate cancer, as an alternative to surgical castration · as an adjuvant treatment to radiotherapy in patients with high-risk localized or locally advanced prostate cancer · as an adjuvant treatment to radical prostatectomy in patients with locally advanced prostate cancer at high risk of disease progression
bi eligard cp (eligard 3 month 22.5mg and mpl-bicalutamide 50mg, 28 pack)
mundipharma pty ltd - leuprorelin acetate, quantity: 22.5 mg - injection, modified release - excipient ingredients: polyglactin; n-methyl-2-pyrrolidone - bicalutamide,treatment of advanced prostate cancer in combination with lhrh agonist therapy.,leuprorelin,eligard? is indicated for the palliative treatment of advanced prostate cancer.
bi eligard cp (eligard 1 month 7.5mg and mpl-bicalutamide 50mg, 28 pack)
mundipharma pty ltd - leuprorelin acetate, quantity: 7.5 mg - injection, modified release - excipient ingredients: n-methyl-2-pyrrolidone; polyglactin - bicalutamide,treatment of advanced prostate cancer in combination with lhrh agonist therapy.,leuprorelin,eligard? is indicated for the palliative treatment of advanced prostate cancer.
bi eligard cp (eligard 3 month 22.5mg and mpl-bicalutamide 50mg, 84 pack)
mundipharma pty ltd - leuprorelin acetate, quantity: 22.5 mg - injection, modified release - excipient ingredients: n-methyl-2-pyrrolidone; polyglactin - bicalutamide,treatment of advanced prostate cancer in combination with lhrh agonist therapy.,leuprorelin,eligard? is indicated for the palliative treatment of advanced prostate cancer.